Log In
BCIQ
Print this Print this
 

TEV-48125 (formerly LBR-101, RN-307)

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionHumanized mAb that blocks the calcitonin gene-related peptide (CGRP) from binding to its receptor
Molecular Target Calcitonin gene-related peptide (CGRP)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationMigraine
Indication DetailsTreat chronic migraine; Treat high frequency episodic migraine
Regulatory Designation
PartnerTeva Pharmaceutical Industries Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$825.0M

$200.0M

$625.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/21/2014

$825.0M

$200.0M

$625.0M

01/07/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today